Orbimed Capital established new holdings in Prelude Therapeutics Incorporat By Investing.com

© Reuters. Orbimed Capital established new holdings in Prelude Therapeutics Incorporat

On the 25th of September, Orbimed Capital purchased 1.2 million Prelude Therapeutics Incorporat (PRLD) shares for $23 million at an average price of $19.00 per share.
Shares of Prelude Therapeutics Incorporat are up 57.52% since the transaction.

Orbimed Capital’s holding in Prelude Therapeutics Incorporat established a new holding of about 917 thousand shares with the purchase.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.